Status:
COMPLETED
Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant
Lead Sponsor:
Mark Stegall
Collaborating Sponsors:
Alexion Pharmaceuticals, Inc.
Conditions:
Kidney Transplant
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
A strongly positive crossmatch has long been considered an absolute contraindication to kidney transplantation and most patients with anti-human leukocyte antigen (HLA) antibody never were able to rec...
Detailed Description
The eculizumab dosing regimen was modified from that used in the treatment of paroxysmal nocturnal hemoglobinuria and consisted of 1200 mg immediately prior to transplantation, 600 mg on postoperative...
Eligibility Criteria
Inclusion
- 18 years of age
- Has end stage renal disease (ESRD) and is to receive a kidney transplant from a living donor (LD) to whom he/she has either:
- A positive crossmatch requiring pretransplant desensitization (defined as a positive T-cell FCXM of greater than or equal to 300 but less than 450 prior to desensitization, or as a positive B-cell FCXM of \> 300 but \< 450 prior to desensitization with demonstrable Class II donor specific alloantibody (DSA) on solid-phase assays). Subsequent to desensitization, patient must have, at the time of transplant, a T-cell and B-cell FCXM less than 300; or
- A positive crossmatch not requiring desensitization (defined as FCXM between 200 and 299)
- Willing to comply with the protocol
- Females of child-bearing potential must have a negative pregnancy test (serum β-HCG) and sexually active females must agree to use a reliable and medically approved method of contraception
- Willing and able to give written informed consent
- Vaccinated against Neisseria meningitides (quadrivalent vaccine), Pneumococcus or H. influenzae at least two weeks prior to beginning desensitization
Exclusion
- Unstable cardiovascular condition
- Previous splenectomy
- Active bacterial or other infection which is clinically significant in the opinion of the investigator
- Known or suspected hereditary complement deficiency
- Participation in any other investigational drug study or was exposed to an investigational drug or device within 30 days of randomization
- Pregnant, breast-feeding, or intending to conceive during the course of the study, including the two month follow-up period after drug discontinuation
- Known hypersensitivity to the treatment drug or any of its excipients
- History of illicit drug use or alcohol abuse within the previous year
- History of meningococcal disease
- Medical condition that, in the opinion of the investigator, might interfere with the patient's participation in the study, pose an added risk for the patient, or confound the assessment of the patient (e.g. severe cardiovascular or pulmonary disease)
- Previously been enrolled in this trial.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2017
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00670774
Start Date
March 1 2008
End Date
August 1 2017
Last Update
June 26 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905